(Q48485316)

11 February 2018

title

Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study (English)

1 reference

11 February 2018

1 reference

7

1 reference

11 February 2018

author name string

T A Rihs

1

1 reference

11 February 2018

K Begley

2

1 reference

11 February 2018

D E Smith

3

1 reference

11 February 2018

J Sarangapany

4

1 reference

11 February 2018

A Callaghan

5

1 reference

11 February 2018

M Kelly

6

1 reference

11 February 2018

J Gold

8

1 reference

11 February 2018

publication date

1 November 2006

1 reference

11 February 2018

published in

HIV Medicine

1 reference

11 February 2018

volume

7

1 reference

11 February 2018

issue

8

1 reference

11 February 2018

page(s)

544-548

1 reference

11 February 2018

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Efavirenz: shifting the HAART paradigm in adult HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

The Cognitive Failures Questionnaire (CFQ) and its correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00419.X

10.1111/J.1468-1293.2006.00419.X

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018